Till innehåll
Contact
Global

Listing on Nasdaq Stockholm
February 2017

Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm

February 8, 2017 – Regulatory press release

Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has, together with HealthCap and Industrifonden (together the “Main Shareholders”), decided to, in order to further the Company’s continued development of its product candidate Ygalo, carry out a broadening of its shareholder base through a new share issue of SEK 650 million (the “Offering”). The Board of Directors of Oncopeptides has applied for a listing of the Company’s shares on Nasdaq Stockholm. Gladiator, SEB-Stiftelsen and Carnegie Asset Management (together the “Cornerstone Investors”) have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 196 million. Furthermore, the Main Shareholders have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 40 million. In connection with the Offering, the Company will also issue new shares as a result of the conversion of the Company’s bridge loans.

Nasdaq Stockholm has approved the application subject to customary conditions. First day of trading in the Company’s shares is expected to be February 22, 2017. Today the Company publishes a prospectus, the price and other terms of the Offering.

Prospectus IPO, Oncopeptides AB (publ)

February 8, 2017

Prospectus Oncopeptides AB (publ) IPO February 7, 2017

pdf, 2 MB

Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm

February 22, 2017 – Regulatory press release

Oncopeptides AB (publ)(”Oncopeptides” or the ”Company”) has, together with HealthCap and Industrifonden (together the “Main Shareholders”), decided to, in order to further the Company’s continued development of its product candidate Ygalo, carry out a broadening of its shareholder base through a new share issue of SEK 650 million (the “Offering”). The Board of Directors of Oncopeptides has applied for a listing of the Company’s shares on Nasdaq Stockholm. Gladiator, SEB-Stiftelsen and Carnegie Asset Management (together the “Cornerstone Investors”) have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 196 million. Furthermore, the Main Shareholders have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 40 million. In connection with the Offering, the Company will also issue new shares as a result of the conversion of the Company’s bridge loans.

Nasdaq Stockholm has approved the application subject to customary conditions. First day of trading in the Company’s shares is expected to be February 22, 2017. Today the Company publishes a prospectus, the price and other terms of the Offering.

Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today

February 22, 2017 – Regulatory press release

Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) hereby announces the outcome relating to the offering to acquire shares in the Company (the “Offering”) and the listing on Nasdaq Stockholm. The Offering attracted strong interest among Swedish and international investors and the Offering was oversubscribed several times.

The Offering in brief

  • As previously announced, the price per share in the Offering was set to 46 SEK per share
  • The Offering includes a share issue of 14,130,434 new shares, corresponding to issue proceeds of SEK 650.0 million (USD 72.9 million[1]) before issue expenses
  • In order to cover potential over-allotment in relation to the Offering, the Company has, at the request of the Joint Global Coordinators (as defined below), committed to issue up to 2,119,565 additional new shares, corresponding to a maximum of 15 percent of the number of shares in the Offering (the “Over-allotment Option”)
  • If the Over-allotment Option is exercised in full, the Offering will comprise 16,249,999 shares in Oncopeptides, corresponding to approximately 39.7 percent of the total number of shares in the Company upon completion of the Offering. The Offering correspond to a total value of SEK 747.5 million (USD 83.8 million1), before issue expenses
  • In connection with the Offering, the Company issues 2,655,781 new shares as a result of a conversion of the Company’s bridge loans
  • Following the conversion of the bridge loans and completion of the Offering and if the Over-allotment Option is exercised in full, the number of shares in the Company will amount to 40,947,680, corresponding to a market value for the total number of shares in the Company after the completion of the Offering of SEK 1,884 million (USD 211.2 million[2])
  • Gladiator, SEB-Stiftelsen och Carnegie Asset Management have together acquired shares in the Offering corresponding to a total value of SEK 196 million. Furthermore, HealthCap and Industrifonden (jointly the “Main Shareholders”) have together acquired shares in the Offering for a total value of SEK 40 million. In total, the pre-existing subscription undertakings amount to 5,130,433 shares, representing approximately 36.3 percent of the number of shares in the Offering or approximately 31.6 percent of the number of shares in the Offering if the Over-allotment Option is exercised in full
  • Following completion of the Offering, the Main Shareholders will remain the largest shareholders in Oncopeptides and will, assuming that the Over-allotment option is exercised in full, hold approximately 28.4 percent each of the total number of shares in the Company
  • Trading in Oncopeptides’ shares on Nasdaq Stockholm commences today, February 22, 2017 under the ticker “ONCO”
  • Trading is conditional until the settlement day, which is expected to be February 24, 2017

Jakob Lindberg, CEO of Oncopeptides:

”We are pleased and very proud of the confidence shown in Oncopeptides by current and new institutional and private investors. The IPO has received strong interest both in Sweden and internationally, which is a sign that investors are confident in our strategy and in our capabilities. The IPO enables us to realise our strategy to continue the development of the product candidate Ygalo for an improved treatment of late-stage relapsed and refractory multiple myeloma. Members of the management team and the board of directors look forward to continue the journey as a listed Company.”

ABG Sundal Collier AB and Carnegie Investment Bank AB (publ) are Joint Global Coordinators and Joint Bookrunners. DNB Markets, a part of DNB Bank ASA, Sweden Branch, is Joint Bookrunner. Setterwalls Advokatbyrå AB is legal advisor to the Company and White & Case Advokat AB is legal advisor to the Joint Global Coordinators and Joint Bookrunners.

This information is information that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on February 22, 2017 at 08.00 a.m. (CET).

[1] FX rate 1 USD = 8.92 SEK
[2] FX rate 1 USD = 8.92 SEK

Company’s CEO Acquires Shares in Oncopeptides

February 24, 2017 – Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company’s CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SEK 1.9M in addition to the shares that he subscribed for in the recent share issue in connection with the IPO.

Read the press release

Change in number of shares and votes in Oncopeptides AB (publ)

February 28, 2017 – Regulatory press release

During February, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 16,786,215 shares and votes due to the new issues of shares that were made in connection with the listing of the Company’s shares on Nasdaq Stockholm. As of February 28, 2017, the number of shares and votes in Oncopeptides amounts to 38,828,115.

Read the press release

On this page

Select language or region
Language
Region
Global

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Our science
Pepaxti®

Learn more about the company Oncopeptides and the work we do to redefine cancer care

About us

Learn more about the company Oncopeptides and the work we do to redefine cancer care

For investors

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Our newsroom
Contact
Global

Disclaimer

Access to the information and documents on this part of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.

DISCLAIMER – IMPORTANT

Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), the United Kingdom, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa or Switzerland, or any other jurisdiction in which such release, publication or distribution might constitute a violation of the local securities laws or regulations of such jurisdiction. We apologise for any inconvenience this may cause. Click here to return to the homepage.

Important information

I am NOT resident or physically located in the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland.

The information contained in this section of Oncopeptides AB (publ)’s (the “Company”) website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

Any securities of the Company referred to on this website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold within the United States absent registration or pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States.

The Securities have also not been and will also not be registered under the applicable securities laws of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland and, subject to certain exemptions, may not be offered or sold in or into or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland. There will be no public offer of the Securities in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland.

Access to the information and documents contained on the following website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage by clicking “I cannot confirm”.

I therefore certify that:

  1. I am resident and physically present outside the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland; and
  2. I am resident and physically present (a) in Sweden or (b) outside Sweden and each of the jurisdictions referred to in clause (1) above and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company.
  3. I have read, understand and agree to comply with all of the restrictions set forth above.

Please scroll through all the information above to continue.

I cannot confirm
I confirm

Not sure if you can access the content? Click here to read the full terms.